statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major...

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial...

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder Neurocrine Biosciences Announces First-Patient Dosed in...

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Neurocrine Biosciences Announces...

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Neurocrine Biosciences, Inc. (NASDAQ:NBIX  Get Free Report) insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction dated Thursday, March 21st. The shares were...

Ingrid Delaet Sells 5,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX  Get Free Report) insider Ingrid Delaet sold 5,000 shares of the businesss stock in a transaction dated Thursday, March 21st. The stock was...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $725,300.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX  Get Free Report)s stock price fell 4.4% on Wednesday . The stock traded as low as $134.25 and last traded at $134.92. 156,489 shares traded...

Neurocrine Biosciences (NASDAQ:NBIX)  Shares Down 4.4%

Thompson Investment Management Inc. lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX  Free Report) by 6.9% during the fourth quarter, Holdings Channel.com reports. The firm...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Thompson Investment Management Inc.

Neurocrine Biosciences (NASDAQ:NBIX  Get Free Report) and Invivyd (NASDAQ:IVVD  Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two...

Comparing Neurocrine Biosciences (NASDAQ:NBIX) & Invivyd (NASDAQ:IVVD)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Volume	717,575.00
52-Wk High	$148.37
52-Wk Low	$89.04

NBIX Neurocrine Biosciences, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals